arrow
H

Hasan Çağrı Yıldırım

ege university
H指数:13
被引数:566

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluation of Olaparib Efficacy Following CDK4/6 Inhibitor Therapy in BRCA-Mutated, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Turkish Oncology Group (TOG) Study

评估奥拉帕利在BRCA突变、激素受体阳性、HER2阴性转移性乳腺癌患者中CDK4/6抑制剂治疗后的疗效:土耳其肿瘤学组(TOG)研究

2026-10-220
PRE
Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

晚期胸腺癌二线治疗的实际疗效:一项多中心土耳其肿瘤学组(TOG)研究

2026-08-270
OA
Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group

三阴性乳腺癌患者辅助内分泌治疗对无病生存期的影响:土耳其肿瘤学组的回顾性多中心队列研究

2026-08-030
OA
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

CDK4/6抑制剂在胚系BRCA1/2突变、激素受体阳性、HER2阴性转移性乳腺癌中的真实世界疗效:土耳其肿瘤学组(TOG)研究

2026-06-170
OA
First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis

围手术期FLOT方案后复发性胃和胃食管结合部癌的一线治疗:土耳其肿瘤学组(TOG)多中心真实世界分析

2026-05-180
PRE
Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG)

在HER2阳性转移性乳腺癌中达到“无疾病证据”的临床意义:土耳其肿瘤学组(TOG)开展的多中心研究

Cancers
IF4.4
2026-03-120
OAAI
Impact of oral nutritional support adherence on muscle strength, body composition, and general health status in gastrointestinal cancer patients: ONMUS study

口服营养支持依从性对胃肠道癌患者肌肉力量、身体成分及整体健康状况的影响:ONMUS研究

2025-12-011
PRE
Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group

曲拉妥单抗(sacituzumab govitecan)在伴有转移性或局部晚期不可切除的三阴性乳腺癌患者中的真实世界有效性与安全性:土耳其肿瘤学组(Turkish Oncology Group)开展的一项多中心研究

2025-10-280
PRE
Real-world comparison of cabozantinib and sunitinib in advanced non-clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group

卡博替尼与舒尼替尼在晚期非透明细胞肾细胞癌中的真实世界比较:土耳其肿瘤学集团的多中心研究

2025-09-010
PRE
Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG)

帕博西利在脂肪肉瘤中的应用:土耳其肿瘤学组(TOG)的真实世界多中心数据

2025-09-010
PRE
PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study
2023-11-014
PRE
Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study
BREAST
IF7.9
2022-12-0112
OAAI